Skip to Content
Merck
  • Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG.

Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG.

Scientific reports (2017-02-06)
Oleg V Pyankov, Yin Xiang Setoh, Sergey A Bodnev, Judith H Edmonds, Olga G Pyankova, Stepan A Pyankov, Gabor Pali, Shane Belford, Louis Lu, Mylinh La, George Lovrecz, Valentina A Volchkova, Keith J Chappell, Daniel Watterson, Glenn Marsh, Paul R Young, Alexander A Agafonov, Jillann F Farmer, Victor E Volchkov, Andreas Suhrbier, Alexander A Khromykh
ABSTRACT

Herein we describe production of purified equine IgG obtained from horses immunized with plasmid DNA followed by boosting with Kunjin replicon virus-like particles both encoding a modified Ebola glycoprotein. Administration of the equine IgG over 5 days to cynomolgus macaques infected 24 hours previously with a lethal dose of Ebola virus suppressed viral loads by more than 5 logs and protected animals from mortality. Animals generated their own Ebola glycoprotein-specific IgG responses 9-15 days after infection, with circulating virus undetectable by day 15-17. Such equine IgG may find utility as a post-exposure prophylactic for Ebola infection and provides a low cost, scalable alternative to monoclonal antibodies, with extensive human safety data and WHO-standardized international manufacturing capability available in both high and low income countries.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Octanoic acid, ≥99%
Sigma-Aldrich
Anti-Monkey IgG (whole molecule)−Peroxidase antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution